## UNITED STATES SECURITIES AND EXCHANGE COMMISSION October 6, 2014

## ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

## Santarus, Inc.

## File No. 0-50651 - CF#31470

Salix Pharmaceuticals, Ltd. (successor to Santarus, Inc.) submitted an application under Rule 24b-2 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on November 12, 2004. The exhibit was refiled, with reduced redactions by Salix with its Form 10-Q filed on August 8, 2014.

Based on representations by Salix, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.4 through September 27, 2017

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary